Owkin and Sanofi are expanding their collaboration to develop agents for drug discovery using artificial intelligence. The partnership, which may be a multi-year agreement, aims to build AI agents for next-generation biopharma. The exact terms and duration of the collaboration are not consistently reported, but it appears to involve the use of Owkin's AI technology to support Sanofi's drug development efforts.